Mizuho Initiates Coverage on Medline (NASDAQ:MDLN)

Investment analysts at Mizuho assumed coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday,Benzinga reports. The firm set an “outperform” rating and a $48.00 price target on the stock. Mizuho’s price objective suggests a potential upside of 18.46% from the stock’s previous close.

MDLN has been the subject of several other research reports. Piper Sandler initiated coverage on Medline in a report on Monday. They issued an “overweight” rating and a $50.00 price objective for the company. Truist Financial set a $52.00 price objective on shares of Medline and gave the company a “buy” rating in a research report on Monday. Morgan Stanley initiated coverage on shares of Medline in a report on Sunday. They issued an “overweight” rating and a $48.00 target price on the stock. Leerink Partners started coverage on Medline in a report on Monday. They set an “outperform” rating and a $48.00 price target for the company. Finally, Royal Bank Of Canada initiated coverage on Medline in a research report on Monday. They set an “outperform” rating and a $47.00 price target on the stock. Eighteen research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $47.25.

Medline Stock Down 1.8%

Shares of NASDAQ MDLN opened at $40.52 on Monday. Medline has a 1-year low of $34.89 and a 1-year high of $45.50.

Insider Buying and Selling

In related news, Director Andrew J. Mills purchased 2,586,206 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the purchase, the director directly owned 2,586,206 shares in the company, valued at $74,999,974. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the sale, the insider directly owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. This represents a 55.88% decrease in their position. The SEC filing for this sale provides additional information.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.